Update on acute otitis media

被引:2
作者
Balter, SE [1 ]
Dowell, SF [1 ]
机构
[1] Ctr Dis Control & Prevent, Epidemiol & Surveillance Div, Natl Immunizat Program, Atlanta, GA 30333 USA
关键词
D O I
10.1097/00001432-200004000-00012
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The increase in drug-resistant Streptococcus pneumoniae has led to concerns about antibiotic resistance. Otitis media is the leading indication for antibiotic use in the United States. Evidence suggests that antibiotics do provide benefit to children with documented acute otitis media, and that carefully selected children may respond to shorter courses of antibiotics. Despite the increase in resistance, amoxicillin remains the drug of choice for acute otitis media even in areas with high levels of resistance. Pneumococcal conjugate vaccine and live attenuated influenza vaccine, which may be licensed in the future, will both have an impact on acute otitis media. During the next few years, these vaccines, along with more stringent diagnostic criteria, and more judicious use of antibiotics, may all contribute towards reducing the incidence of acute otitis media, the number of antibiotic prescriptions given and the adverse impact of antimicrobial resistance. Curr Opin Infect Dis 13:165-170. (C) 2000 Lippincott Williams & Wilkins.
引用
收藏
页码:165 / 170
页数:6
相关论文
共 40 条
[1]   Immune response to pneumococcal conjugate and polysaccharide vaccines in otitis-prone and otitis-free children [J].
Barnett, ED ;
Pelton, SI ;
Cabral, HJ ;
Eavey, RD ;
Allen, C ;
Cunningham, MJ ;
McNamara, ER ;
Klein, JO .
CLINICAL INFECTIOUS DISEASES, 1999, 29 (01) :191-192
[2]   The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children [J].
Belshe, RB ;
Mendelman, PM ;
Treanor, J ;
King, J ;
Gruber, WC ;
Piedra, P ;
Bernstein, DI ;
Hayden, FG ;
Kotloff, K ;
Zangwill, K ;
Iacuzio, D ;
Wolff, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (20) :1405-1412
[3]  
BLACK SB, 1998, 38 INT C ANT AG CHEM
[4]   Safety and tolerability of a new formulation (90 mg/kg/day divided every 12 h) of amoxicillin/clavulanate (Augmentin®) in the empiric treatment of pediatric acute otitis media caused by drug-resistant Streptococcus pneumoniae [J].
Bottenfield, GW ;
Burch, DJ ;
Hedrick, JA ;
Schaten, R ;
Rowinski, CA ;
Davies, JT .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1998, 17 (10) :963-968
[5]   Pneumococcal conjugate vaccine primes for polysaccharide-inducible IgG2 antibody response in children with recurrent otitis media acuta [J].
Breukels, MA ;
Rijkers, GT ;
Voorhorst-Ogink, MM ;
Zegers, BJM ;
Sanders, LAM .
JOURNAL OF INFECTIOUS DISEASES, 1999, 179 (05) :1152-1156
[6]  
Cantekin EI, 1998, JAMA-J AM MED ASSOC, V280, P1903, DOI 10.1001/jama.280.22.1903
[7]  
Cates C, 1999, BRIT MED J, V318, P715, DOI 10.1136/bmj.318.7185.715
[8]  
*CDC, 1997, MMWR-MORBID MORTAL W, V46, pRR8
[9]   INFLUENZA-A VACCINE DECREASES THE INCIDENCE OF OTITIS-MEDIA IN 6- TO 30-MONTH-OLD CHILDREN IN DAY-CARE [J].
CLEMENTS, DA ;
LANGDON, L ;
BLAND, C ;
WALTER, E .
ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE, 1995, 149 (10) :1113-1117
[10]   A multicenter, randomized, double-blind trial of 5 versus 10 days of antibiotic therapy for acute otitis media in young children [J].
Cohen, R ;
Levy, C ;
Boucherat, M ;
Langue, J ;
de La Rocque, F .
JOURNAL OF PEDIATRICS, 1998, 133 (05) :634-639